Home Health System Tracker Series

Peterson-KFF Health System Tracker

The Peterson-KFF Health System Tracker is an online hub monitoring how well the U.S. health system is operating through key quality and cost measures. A partnership of the Peterson Center on Healthcare and KFF, the Tracker documents trends in Health Spending, Quality of Care, Access & Affordability, and Health & Wellbeing through issue briefs and downloadable chart collections. The Tracker also includes the Interactive Health Spending Explorer tool, which helps users analyze more than 50 years of health expenditure data, and a Health System Dashboard, which provides quick and easy access to the latest, most relevant statistics.

View the Latest: Health System Tracker

Filter

List Grid

41-50 of 183 results

  • Beyond Cost, What Barriers to Health Care do Consumers Face?

    Issue Brief

    High cost-sharing and expenses not covered by insurance leave some people with expensive medical bills. But costs are not the only barriers to health care access. According to KFF's new analysis, many adults can face logistical barriers to care, like work schedules or finding a doctor in network or appointment. In 2022, about 1 in 5 adults under age 65 experienced at least one barrier to accessing care aside from cost. The full analysis and…

  • What are the Trends in Health Utilization and Spending in Early 2024?

    Issue Brief

    Recent trends in healthcare utilization and spending suggest that most spending on health services exceeds pre-pandemic levels and health costs are growing at a faster rate than in recent years. However, utilization of care has been uneven by setting and market.

  • How Many People with Employer-Sponsored Insurance Use the Drugs Slated for Medicare Price Negotiations

    Issue Brief

    Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis. The most used drug for people with employer-sponsored health insurance was Jardiance, a drug used to treat diabetes and heart failure, which was taken by more than 911,000 enrollees. The analysis uses the Merative MarketScan 2022 commercial claims to estimate the number of enrollees…

  • Marketplace Insurers are Proposing a 7% Average Premium Hike for 2025 and Pointing to Rising Hospital Prices and GLP-1 Drugs as Key Drivers of Costs

    News Release

    ACA Marketplace insurers are proposing a median premium increase of 7% for 2025, similar to the 6% premium increase filed for 2024, according to a new KFF analysis of the preliminary rate filings. Insurers’ proposed rate changes – most of which fall between 2% and 10% – may change during the review process. Although the vast majority of Marketplace enrollees receive subsidies and are not expected to face these added costs, premium increases generally result…

  • How Much and Why ACA Marketplace Premiums Are Going Up in 2025

    Issue Brief

    This analysis of insurers' preliminary rate filings shows that ACA Marketplace insurers are requesting a median premium increase of 7% for 2025, similar to the 6% premium increase filed for 2024. Insurers cite growing health care prices – particularly for hospital care – as a key driver of premium growth in 2025.

  • What Drives Health Spending in the U.S. Compared to Other Countries

    Issue Brief

    An updated issue brief looks at the drivers of health spending in the U.S. and key differences between the U.S. and other large, wealthy nations. The analysis finds that people in the U.S. spent $5,683 more per person on health care compared to those in similarly large and wealthy countries. Almost 80% of the difference in spending came from inpatient and outpatient care costs. Many retail prescription drugs also cost more in the U.S. In…

  • Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans

    News Release

    Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes. When GLP-1 drugs are covered…

  • Insurer Strategies to Control Costs Associated with Weight Loss Drugs

    Issue Brief

    Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes. This analysis examines publicly available formularies…